Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
#2964 Personalized Therapy in a Case of Esophageal NEC Based on Tumor Genome Sequencing
Introduction: High-grade esophageal neuroendocrine carcinomas (NEC) constitute a rare subgroup of neuroendocrine neoplasms, with a particularly aggressive behaviour and unfavourable prognosis. To date, there are no validated biomarkers for personalized therapy and cytotoxic chemotherapy remains the standard of care. However, tumor genome sequencing may help improve NEC molecular landscape knowledge in order to identify novel targets for an individualized approach.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: La Salvia A
Authors: La Salvia A, Espinosa Olarte P, Modrego Sanchez A, Riesco Martinez M, Garcia Carbonero R,
Keywords: Esophageal neuroendocrine carcinoma, tumor genome sequencing, immunotherapy, tumor burden, personalized therapy,
Introduction: ENETS requires Centers of Excellence to discuss all new gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients in a multidisciplinary tumor board (MDT) but the true value of the MDT has never been assessed
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Zandee W
Authors: Zandee W, Merola E, de Mestier L, Klümpen H, Geboes K,
Keywords: Standard of Care, Multidisciplinary Tumor Board, Quality of Care,
Introduction: SSA represent the standard of care for controlling symptoms of patients with functional GEP-NEN and have anti-proliferative effects. Molecular targeted therapies (MTT) against angiogenesis resulted in an increased PFS, however, due to primary and acquired resistance to MTT, the impact on OS remains unclear. One of the most pivotal questions, whether combining SSA with novel MTT will result in enhanced anti-proliferative activity compared to monotherapy treatment, are lacking.
Conference: 14th Annual ENETSConcerence (2017)
Presenting Author: Krug S
Authors: Krug S, Gress T, Theuerkorn K, Mordhorst J, Michl P,
Keywords: SSA, targeted therapies, SSTR,
Introduction: The international phase 3 CLARINET study showed that treatment with the somatostatin analog (SSA) lanreotide was associated with significantly prolonged PFS vs PBO in GEP-NETs, leading to a new indication approved in more than 35 countries. Like GEP-NETs, lung NETs express somatostatin receptors.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Reidy-Lagunes D
Authors: Reidy-Lagunes D, Kulke M, Wolin E, Mirakhur B, Massien C,
Keywords: Lung NETs, lanreotide,
Introduction: Pancreatic neuroendocrine tumors (pNETs) and intraductal papillary mucinous neoplasms (IPMN) are increasingly recognized pancreatic tumors due to advances in imaging. Standard of care is surgical resection for these tumors is via the appropriate procedure: pancreaticoduodenectomy or enucleation.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Arora A
Authors: Arora A, Scudamore C, Flint J,
Keywords: Pancreatic neuroendocrine tumor, IPMN, uncinatectomy ,